Tensions have risen between White House officials and HHS Secretary Alex Azar; a life-saving bladder cancer drug is in short supply; suicide rates for children and young adults have soared.
Tensions have widened the rift between White House officials and HHS Secretary Alex Azar, POLITICO reported, resulting in impeded projects, disputes over Medicaid and fetal tissue research, complicating drug pricing reform, and spurring personal attacks, according to current and former White House aides and HHS officials. The White House called the disagreements part of the deliberative policy process while HHS downplayed the disputes. Azar is believed not to be at risk of being fired despite the recent tensions.
While drug shortages are sometimes caused by production errors, quality problems, and natural disasters, the example of a low-cost, gold standard immunotherapy drug for bladder cancer illustrates another reason—some believe the price is set too low and discourage others from making the off-patent drug. Desperate patients are searching for a Merck drug, called BCG, a live, weakened bacteria that takes 3 months to make, The Washington Post reported.
A study in JAMA found that suicide rates for teens and young adults have reached the highest level since 2000, especially for young men, while the rate for females steadily increased. A total of 5016 males and 1225 females between 15 to 24 years old took their own lives in 2017. At ages 15 to 19 years, the rate of suicides was 11.8 per 100,000 (17.9 per 100,000 in males and 5.4 per 100,000 in females). In young adults aged 20 to 24 years, the suicide rate for males and females combined in 2017 was 17 per 100,000; in males, 27.1 per 100,000; and in females, 6.2 per 100,000.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Report Reveals Mounting Burdens of Drug Shortages on US Health System
June 27th 2025Vizient's 2024 survey reveals a sharp rise in drug shortages across US health care, with pediatric care hit especially hard and labor costs soaring—but the true impact may go far beyond limited medication access, threatening to disrupt the very foundations of how health systems operate.
Read More